SCHEMBL14716944

SCHEMBL14716944

Cc1ccc(NC(=O)c2ccc(N3CC[C@@H](N(C)C)C3)c(C(F)(F)F)c2)cc1NC(=O)c1csc2c(NC3CC3)ncnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 14/20 0.52
CSF1R P07333 1/20 0.46
ABL1 P00519 5/20 0.46
SRC P12931 1/20 0.46
LYN P07948 3/20 0.44
BCR P11274 2/20 0.44
RIPK2 O43353 1/20 0.44
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
RET P07949 1/20 0.44
PDGFRB P09619 1/20 0.44
ARAF P10398 1/20 0.44
NQO2 P16083 1/20 0.44
EPHA2 P29317 1/20 0.44
EPHB2 P29323 1/20 0.44
CSK P41240 1/20 0.44
ABL2 P42684 1/20 0.44
FRK P42685 1/20 0.44
MAPKAPK2 P49137 1/20 0.44
IRAK1 P51617 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14716947 1.00 BRAF (0.52) BRAFCSF1RABL1SRCLYN
SCHEMBL14717716 1.00 BRAF (0.52) BRAFCSF1RABL1SRCLYN
SCHEMBL2313598 0.94 BRAF (0.48) BRAFABL1SRCLCKEML4
SCHEMBL2313601 0.94 BRAF (0.48) BRAFABL1SRCLCKEML4
SCHEMBL14717844 0.94 BRAF (0.48) BRAFABL1SRCLCKEML4
SCHEMBL19073339 0.91 BRAF (0.48) BRAFABL1SRCEGFR
SCHEMBL12432453 0.90 BRAF (0.53) BRAFABL1SRCEGFR
SCHEMBL14717309 0.89 ABL1 (0.57) BRAFABL1LYNBCRRIPK2
SCHEMBL12433481 0.89 ABL1 (0.57) BRAFABL1LYNBCRRIPK2
SCHEMBL2365003 0.89 BRAF (0.53) BRAFABL1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP claimed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US claimed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US claimed
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES CDK2, TK1, DTYMK BRAF 60/4885CSF1R 3387/4885ABL1 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.